Axonics to Report First Quarter 2023 Financial Results on May 1

Rhea-AI Summary

Axonics, Inc. (NASDAQ: AXNX) will report its first quarter 2023 financial results after market close on May 1, 2023. A conference call is scheduled for 4:30 p.m. Eastern Time to discuss these results. Interested parties can register for the call via the provided link or join the webcast. Axonics specializes in innovative treatments for bladder and bowel dysfunction and has gained recognition, ranking No. 2 in the 2023 Financial Times fastest-growing companies in the Americas and No. 4 in the Deloitte Technology Fast 500 for 2022. The company offers clinically proven products, such as sacral neuromodulation systems and Bulkamid® for urinary incontinence, affecting millions of adults in the U.S. Furthermore, reimbursement for its services is well-established in the U.S. and most European territories.

Positive

• Ranked No. 2 on the Financial Times 2023 fastest growing companies in the Americas.
• Ranked No. 4 on Deloitte's 2022 Technology Fast 500.
• Established reimbursement coverage in the U.S. and most European countries.

Negative

• None.

IRVINE, Calif.--(BUSINESS WIRE)-- Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, is scheduled to report first quarter 2023 financial results after the close of trading on Monday, May 1.

Axonics will host a conference call at 4:30 p.m. Eastern Time to discuss financial results. To access the conference call by telephone, interested parties may register at the following link: Axonics 1Q23 registration.

For those not planning to ask a question, the company recommends accessing the conference call by webcast at the following link: Axonics 1Q23 webcast. A replay of the webcast will be archived in the Events section of the Axonics investor relations website.

About Axonics

Axonics is a global medical technology company that is developing and commercializing novel products for adults with bladder and bowel dysfunction. Axonics recently ranked No. 2 on the 2023 Financial Times ranking of the fastest growing companies in the Americas and No. 4 on the 2022 Deloitte Technology Fast 500.

Axonics^® sacral neuromodulation systems provide adults with overactive bladder and/or fecal incontinence with long-lived, easy to use, safe, clinically effective therapy. In addition, the company’s best-in-class urethral bulking hydrogel, Bulkamid^®, provides safe and durable symptom relief to women with stress urinary incontinence. In the U.S., moderate to severe urinary incontinence affects an estimated 28 million women and fecal incontinence affects an estimated 19 million adults. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230410005145/en/

Axonics contact:

Neil Bhalodkar

949-336-5293

IR@axonics.com

Source: Axonics, Inc.

FAQ

What are Axonics' financial results for Q1 2023?

Axonics will report its Q1 2023 financial results on May 1, 2023.

When is the Axonics conference call scheduled?

The conference call is scheduled for 4:30 p.m. Eastern Time on May 1, 2023.

What products does Axonics offer for bladder dysfunction?

Axonics provides sacral neuromodulation systems and Bulkamid® for treating bladder and bowel dysfunction.

Where can I access the Axonics Q1 2023 conference call?

The conference call can be accessed via telephone registration or a live webcast.

What does the reimbursement coverage look like for Axonics products?

Reimbursement coverage for Axonics products is well-established in the U.S. and is a covered service in most European countries.